Space infrastructure company Redwire Corporation (NYSE: RDW) on Wednesday announced a collaboration with biopharmaceutical company Bristol Myers Squibb (BMS) to study small molecule drug compounds aboard the International Space Station (ISS).
Utilising Redwire's PIL-BOX pharmaceutical development platform, this mission aims to enhance drug stability, streamline manufacturing, and improve efficiencies across oncology, immunology, and cardiovascular therapies.
In addition, Redwire is launching another PIL-BOX investigation with ExesaLibero Pharma, targeting ELP-004, a drug that addresses excess bone removal linked to conditions like rheumatoid arthritis, multiple myeloma and certain cancers. This mission will support the development of advanced treatments for bone diseases.
A third experiment, conducted with Butler University, seeks to produce high-quality seed crystals in microgravity, potentially advancing pharmaceutical production on Earth. This is Butler's second investigation using PIL-BOX.
Redwire has launched 16 PIL-BOX missions to date, with 12 more scheduled aboard the upcoming SpaceX-31 cargo resupply flight to the ISS. The company aims to drive breakthroughs in drug development and other advanced technologies with significant commercial potential through its space-based research initiatives.
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
NeuroSense Therapeutics pursues early commercialisation of ALS treatment in Canada
Ananda Developments PLC signs contract for Phase 1 PK study on MRX1
Lundbeck launches clinical trial for CD40L blocker Lu AG22515
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Pfizer names new Regional President for Middle East, Russia and Africa
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps